ABOUT THIS PODCAST 🔗

Update frequency:
every 20 days
Average audio length:
42 minutes
Guest interviews
English
United States
93 episodes
since Sept. 27, 2023
episodic

LATEST EPISODE 🔗

Neuroscience has one of the toughest track records in drug development. Large trials enroll hundreds of patients, struggle with placebo response, and often end with teams chasing subgroups in secondary endpoints. In this episode of Power to the Patients, host Brandon Li speaks with two experts who …

SEARCH PAST EPISODES

Search past episodes of Power to the Patients.

PREVIOUS EPISODES

Drug discovery from nature is not a new idea. It is one of pharma’s oldest ideas. Aspirin, metformin, and many other small molecule drugs trace their origins back to natural sources. Historically, the bottleneck was complexity. Finding a single active molecule inside a plant with 10,000 unique comp…
For many ovarian cancer patients, platinum-based chemotherapy works well at first. Then resistance begins: the tumor adapts, treatment loses effect, and clinical options narrow. That is the clinical problem Thomas Zindrick and his team at Genelux Corporation are trying to address with their lead ca…
Gout is often treated solely as a lifestyle problem. James Mackay calls that a myth.  In this episode of Power to the Patients, host Brandon Li sits down with James, CEO and co-founder of Crystalys Therapeutics, to unpack why gout has been misunderstood, under-prioritized, and under-innovated …
Learn more about Alzheimer's disease drug development and clinical trial design for small molecule therapies using biomarkers in Alzheimer's research, and AI in drug development. Solving neurodegeneration requires redefining how we view the timeline of disease. While billions have been spent on amy…
In this episode of Power to the Patients, host Brandon Li speaks with Dr. Aaron Koenig, Chief Medical Officer at Delix Therapeutics, about the emerging field of neuroplasticogens and the effort to develop medicines that promote neuroplasticity without the hallucinogenic effects associated with psyc…
Psychedelic therapy for postpartum depression shows breakthrough results. Reunion Neuroscience CEO Greg Mayes details luvesilocin clinical trials. While many developers focus on treatment-resistant depression, Reunion is carving a path through postpartum depression and adjustment disorder. Greg sha…
Psychiatry has long been considered one of the most complex and least understood areas of medicine. While other therapeutic fields have advanced rapidly with clear biomarkers and objective endpoints, mental health has remained rooted in subjective assessments and decades-old treatment approaches. I…
Kidney disease affects 37 million people and is now the ninth leading cause of death globally. Yet despite its scale and severity, it has largely been absent from the precision medicine revolution that reshaped oncology. In this episode of Power to the Patients, Jason Coloma, CEO of Maze Therapeuti…
In this episode of Power to the Patients, Brandon Li speaks with Dr. Ken Sharlin, a neurologist and principal investigator with decades of experience across clinical practice, functional medicine, and clinical research. Dr. Sharlin shares his journey from traditional academic neurology to a systems…
Disclaimer: The podcast and artwork embedded on this page are from Brandon Li, which is the property of its owner and not affiliated with or endorsed by Listen Notes, Inc.